BR112017017303A2 - método para obtenção de clones de células de alta produtividade, linhagem de células de mieloma, e, anticorpo recombinante humanizado. - Google Patents
método para obtenção de clones de células de alta produtividade, linhagem de células de mieloma, e, anticorpo recombinante humanizado.Info
- Publication number
- BR112017017303A2 BR112017017303A2 BR112017017303-4A BR112017017303A BR112017017303A2 BR 112017017303 A2 BR112017017303 A2 BR 112017017303A2 BR 112017017303 A BR112017017303 A BR 112017017303A BR 112017017303 A2 BR112017017303 A2 BR 112017017303A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- culture medium
- cell clones
- high yield
- antibody molecule
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000001963 growth medium Substances 0.000 abstract 3
- 230000006978 adaptation Effects 0.000 abstract 2
- 238000000855 fermentation Methods 0.000 abstract 2
- 230000004151 fermentation Effects 0.000 abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 239000002609 medium Substances 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 230000010412 perfusion Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000010473 stable expression Effects 0.000 abstract 1
- 230000003068 static effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
é fornecido um método para a obtenção de clones de células de expressão estável de alto rendimento a partir de linhagens de células de mieloma em um meio de cultura isento de proteína. o método é usado para a produção industrial de um anticorpo recombinante e inclui três estágios: (1) adaptação a um meio de cultura isento de proteína, cultura estática de células em uma baixa densidade e redução gradual de um suplemento rico em gordura para um meio de cultura químico; (2) adaptação a um meio de cultura isento de proteína; cultura de células em uma alta densidade e uso de um sistema de fermentação por perfusão em escala laboratorial; e (3) rastreamento de clones de células de expressão estável de alto rendimento das células após a fermentação terminar. o clone celular pode ser usado para produzir um anticorpo recombinante anti-neugcgm3 14f7 humanizado.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510080631.3A CN104651314B (zh) | 2015-02-14 | 2015-02-14 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
| CN201510080631.3 | 2015-02-14 | ||
| PCT/CN2016/076135 WO2016127954A1 (zh) | 2015-02-14 | 2016-03-11 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112017017303A2 true BR112017017303A2 (pt) | 2018-04-10 |
| BR112017017303B1 BR112017017303B1 (pt) | 2023-08-08 |
| BR112017017303B8 BR112017017303B8 (pt) | 2024-03-05 |
Family
ID=53242962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017017303A BR112017017303B8 (pt) | 2015-02-14 | 2016-03-11 | Método para obtenção de clones de células de alta produtividade |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10457747B2 (pt) |
| JP (1) | JP2018506306A (pt) |
| KR (1) | KR20180029948A (pt) |
| CN (1) | CN104651314B (pt) |
| AU (1) | AU2016218641C1 (pt) |
| BR (1) | BR112017017303B8 (pt) |
| CA (1) | CA2974027C (pt) |
| CO (1) | CO2017008087A2 (pt) |
| CU (1) | CU20170106A7 (pt) |
| EA (1) | EA201791828A1 (pt) |
| IL (1) | IL253932A0 (pt) |
| MX (1) | MX2017010421A (pt) |
| MY (1) | MY192147A (pt) |
| NZ (1) | NZ735485A (pt) |
| SG (1) | SG11201706595TA (pt) |
| TN (1) | TN2017000302A1 (pt) |
| WO (1) | WO2016127954A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104651314B (zh) * | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
| EP3257935A4 (en) * | 2016-03-11 | 2018-08-08 | Biotech Pharmaceutical Co. Ltd. | Method for obtaining high-yield, stable-expression cell clones and antibody molecules obtained thereby |
| CN113480652B (zh) * | 2021-07-30 | 2023-04-07 | 成都景泽生物制药有限公司 | 一种重组cho细胞发酵培养生产重组egfr抗体活性分子的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22731A1 (es) * | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
| GB0208041D0 (en) * | 2002-04-08 | 2002-05-22 | Lonza Biologics Plc | Method of culturing animal cells |
| CU23097A1 (es) * | 2002-10-23 | 2005-11-18 | Centro Inmunologia Molecular | Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método |
| CU23403A1 (es) * | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| EP1689878A4 (en) * | 2003-11-03 | 2007-02-14 | Centocor Inc | METHOD FOR MAINTAINING LOW SHEAR IN A BIOTECHNOLOGICAL SYSTEM |
| CU24120B1 (es) * | 2012-03-01 | 2015-08-27 | Ct De Inmunología Molecular | Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3 |
| CN104152415B (zh) * | 2014-08-13 | 2015-09-30 | 百泰生物药业有限公司 | 获得高产稳定表达重组抗体的骨髓瘤细胞株的方法及应用 |
| CN104651314B (zh) * | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
-
2015
- 2015-02-14 CN CN201510080631.3A patent/CN104651314B/zh active Active
-
2016
- 2016-03-11 CA CA2974027A patent/CA2974027C/en active Active
- 2016-03-11 BR BR112017017303A patent/BR112017017303B8/pt active IP Right Grant
- 2016-03-11 TN TNP/2017/000302A patent/TN2017000302A1/en unknown
- 2016-03-11 KR KR1020177022618A patent/KR20180029948A/ko not_active Application Discontinuation
- 2016-03-11 NZ NZ735485A patent/NZ735485A/en active IP Right Revival
- 2016-03-11 MY MYPI2017702967A patent/MY192147A/en unknown
- 2016-03-11 MX MX2017010421A patent/MX2017010421A/es unknown
- 2016-03-11 AU AU2016218641A patent/AU2016218641C1/en active Active
- 2016-03-11 CU CUP2017000106A patent/CU20170106A7/xx unknown
- 2016-03-11 SG SG11201706595TA patent/SG11201706595TA/en unknown
- 2016-03-11 JP JP2017560865A patent/JP2018506306A/ja active Pending
- 2016-03-11 WO PCT/CN2016/076135 patent/WO2016127954A1/zh active Application Filing
- 2016-03-11 US US15/549,087 patent/US10457747B2/en active Active
- 2016-03-11 EA EA201791828A patent/EA201791828A1/ru unknown
-
2017
- 2017-08-09 IL IL253932A patent/IL253932A0/en unknown
- 2017-08-10 CO CONC2017/0008087A patent/CO2017008087A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CU20170106A7 (es) | 2018-06-05 |
| MX2017010421A (es) | 2018-04-26 |
| AU2016218641B2 (en) | 2019-10-31 |
| CA2974027A1 (en) | 2016-08-18 |
| IL253932A0 (en) | 2017-10-31 |
| AU2016218641C1 (en) | 2020-02-27 |
| JP2018506306A (ja) | 2018-03-08 |
| KR20180029948A (ko) | 2018-03-21 |
| MY192147A (en) | 2022-08-01 |
| TN2017000302A1 (en) | 2019-01-16 |
| NZ735485A (en) | 2019-08-30 |
| BR112017017303B8 (pt) | 2024-03-05 |
| SG11201706595TA (en) | 2017-09-28 |
| US20180016353A1 (en) | 2018-01-18 |
| AU2016218641A1 (en) | 2017-10-05 |
| US10457747B2 (en) | 2019-10-29 |
| BR112017017303B1 (pt) | 2023-08-08 |
| CA2974027C (en) | 2021-02-16 |
| CO2017008087A2 (es) | 2017-10-10 |
| WO2016127954A1 (zh) | 2016-08-18 |
| CN104651314A (zh) | 2015-05-27 |
| EA201791828A1 (ru) | 2017-12-29 |
| CN104651314B (zh) | 2018-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201270213A1 (ru) | Способ получения полипептида или вируса, представляющих интерес, в непрерывной клеточной культуре | |
| BR112018002214A2 (pt) | ?métodos para cultivar células e para produzir uma proteína, meios de cultura de células cho e de batelada alimentada e/ou alimentação, e, alimentação de cultura de células cho? | |
| BR112018008648A2 (pt) | métodos de geração de células t a partir de células tronco e métodos imunoterapêuticos ao usar células t | |
| EA201290797A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ АДЕНОВИРУСНЫХ ВЕКТОРОВ Ad26 | |
| EA201991976A1 (ru) | Метаболически оптимизированная клеточная культура | |
| BR112015019950A2 (pt) | Método para gerar linhagem de células-tronco embrionárias (es) de rato, e, cultura in vitro | |
| EA201170638A1 (ru) | Способ получения аденовирусных векторов | |
| EA202091407A1 (ru) | Состав бессывороточной среды для культивирования клеток и способы его применения | |
| EA201171018A1 (ru) | Биореактор для культивирования клеток млекопитающих | |
| MY169935A (en) | "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof" | |
| AR077369A1 (es) | Metodopara producir eritrocitos sin celulas alimentadoras | |
| BR112018011902A2 (pt) | método de fermentação, levedura geneticamente modificada, construto de ácido nucleico, vetor, célula hospedeira, meio de fermentação e utilização da levedura geneticamente modificada | |
| NZ715246A (en) | Improved process for production of monoclonal antibodies | |
| BR112017017303A2 (pt) | método para obtenção de clones de células de alta produtividade, linhagem de células de mieloma, e, anticorpo recombinante humanizado. | |
| EA202091422A1 (ru) | Способ непрерывного производства продуктов на основе биспецифических антител | |
| BR112015021993A8 (pt) | polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular | |
| SG10201902355VA (en) | Ultra-high density cell banking methods | |
| BR112016028512A8 (pt) | método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante | |
| BR112015022529A2 (pt) | meios de cultura de células e processos de produção de anticorpo | |
| BR112018068303A2 (pt) | método de cultivo e/ou monitoramento de células epiteliais usando um sistema de cultura celular microfluida, uso das células no sistema de cultura celular microfluida, composição ou sistema e sistema de cultura celular microfluida | |
| EA201492185A1 (ru) | Способ получения рекомбинантной идуронат-2-сульфатазы | |
| BR112017023624A2 (pt) | método de cultivo em pequena escala para células em suspensão | |
| EA202091349A1 (ru) | Способы культивирования клеток | |
| BR112018007590A2 (pt) | método para produzir proteína de fusão que tem domínio fc de igg | |
| RU2018130530A (ru) | Способ получения активного фактора роста гепатоцитов (hgf) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/2016, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2744 DE 08/08/2023, QUANTO AO ITEM (54) TITULO. |